Imugene Limited Imugene (ASX:IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines.
Quarterly Activities and Cash Flow Report Quarter ended 31 December 2019 31/01/2020 10:15:00 Key Highlights: Imugene completes oversubscribed placement of $24.6 million to fund clinical programs on 02- December, 2019 Professor Yuman Fong appointed Chairman of the Oncolytic Virotherapy S…
Imugene PD1-Vaxx Immunotherapy Update 28/01/2020 09:25:00 Sydney, Australia, 28 January 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announces a clinical development update on its PD1-Vaxx cancer immunotherapy. PD1- Vaxx w…
Imugene HER-Vaxx Immunotherapy Patent Granted in United States 14/01/2020 09:46:00 Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced it has received a Notice of Grant from the United States Patent and Trademark Office (USPTO) for Patent Application…
Company News / by Michael Luu - 14 days ago Imugene (ASX:IMU) to proceed to final dose cohort for lung cancer treatment 07 Apr 2021 - $620 million cancer treatment provider Imugene (ASX:IMU) has announced that an independent team of researchers have certified that lung cancer drug PD1-Vaxx is safe f…
Market Reports / by Katrina Bullock - 6 months ago President Trump contracts Covid-19: Aus shares close 1.4% lower 02 Oct 2020 - The Aussie dollar has toppled, and US futures are looking bleak after confirmation that President Donald Trump and First Lady Melania Trump have contracted Covid-19. …
Company News / by Katrina Bullock - 6 months ago Imugene (ASX:IMU) secures core US patent 02 Oct 2020 - Immuno-oncology company, Imugene (ASX:IMU) has been granted a patent from the US United States Patent and Trademark Office which it says protects its cancer growth fa…
Company News / by Rachael Jones - A year ago Imugene (ASX:IMU) report PD1-Vaxx generates high levels of antibodies 28 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) report that studies have shown their PD1-Vaxx cancer immunotherapy drug generates high levels of antibodies.
Market Reports / by Ortenzia Borre - A year ago Lithium shares continue to rally: Aus shares close 0.9% higher 14 Jan 2020 - It’s been a positive day of trade for the Australian share market closing 0.9 per cent higher. Kangaroo Island Plantation Timbers (ASX:KPT) report further damage.
Company News / by Anna Napoli - A year ago Imugene (ASX:IMU) receives US patent approval for HER-VAxx 14 Jan 2020 - Immuno-therapy company Imugene (ASX:IMU) has received the US patent for its HER-VAxx cancer treatment.
Market Reports / by Ortenzia Borre - A year ago Imugene Limited (ASX:IMU) completes OV acquisition: Aus shares 0.6% lower at noon 18 Nov 2019 - Australian share market dipped on open despite ‘constructive discussions’ regarding the phase-one China and US trade deal between negotiators. Imugene Limited (ASX:IM…
Market Reports / by Jessica Amir - A year ago RBA cut rates to historical low, banks under pressure: Aus shares close 0.1% higher 02 Jul 2019 - Australian share market falls after RBA cut rates as expected to 1%, but the ASX200 claws back into positive territory, rising for the 2nd session. Financials lost ov…
Company Presentations / by - A year ago Imugene (ASX:IMU) Presentation, FNN Investor Event, May 2019, Sydney 27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong presents on trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vac…
Interviews / by Anna Napoli - A year ago Imugene (ASX:IMU) targeting gastric cancer 27 May 2019 - Imugene Limited (ASX:IMU) Managing Director & CEO, Leslie Chong discusses trial progress with the company's HER-B Vaxx cancer vaccines, the advantages of B-cell vacci…
Company News / by Rachael Jones - A year ago Imugene’s HER-Vaxx to be presented at US oncology meeting 29 Apr 2019 - Immuno-oncology company Imugene (ASX:IMU) will present data from its Phase Ib study of its HER-Vaxx cancer vaccine at the prestigious American Society of Clinical Onc…
Company News / by Rachael Jones - A year ago Imugene appoints Dr Lesley Russell to the board 23 Apr 2019 - Immuno-oncology company Imugene (ASX:IMU) has appointed Dr Lesley Russell as a Non-Executive Director, a leading global pharmaceutical executive.
Company News / by Rachael Jones - 2 years ago Imugene presents new data on cancer vaccines AACR 02 Apr 2019 - Biotech company Imugene (ASX:IMU) presented new data on the KEY-Vaxx and B-Vaxx cancer vaccine programs at the American Association for Cancer Research Annual Meeting…
Market Reports / by Katrina Bullock - 2 years ago Linius Technologies displays new blockchain tech: Aus shares 0.9% higher at noon 22 Mar 2019 - The S&P/ASX 200 opened higher this morning following strong leads from Wall Street where US equities reached a five-month high. The market continues to rally into the…
Company News / by Rachael Jones - 2 years ago Imugene doses first patient in Moldova with cancer vaccine 14 Mar 2019 - Immuno-oncology company Imugene (ASX:IMU) has dosed the first patient in Moldova in Eastern Europe for the treatment of HER-2 positive gastric cancer.
Company News / by Anna Napoli - 2 years ago Imugene appoints distinguished scientist to SAB 07 Jan 2019 - Imugene (ASX:IMU) has today announced the appointment of distinguished scientist, Dr Michael Caligiuri to its Scientific Advisory Board.
Company Presentations / by - 2 years ago Imugene (ASX:IMU) Presentation, FNN Investor Event, October 2018, Sydney 26 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong presents on the company's trial progress with its lead HER-Vaxx cancer vaccine, advantages of B-cell…
Interviews / by Rachael Jones - 2 years ago Imugene (ASX:IMU) targeting gastric cancer 29 Oct 2018 - Imugene Limited (ASX:IMU) Managing Director and CEO, Leslie Chong talks trial progress with the company's lead HER-Vaxx cancer vaccine, advantages of B-cell vaccines …
Market Reports / by Rachael Jones - 2 years ago Healthcare sector stays in the green: ASX closes 0.6% lower 01 Oct 2018 - It's been a quiet day on the markets with the ASX closing lower. New Zealand software company Xero did well today, Nufarm shares were down. The Canadian dollar and Me…
Company News / by Anna Napoli - 2 years ago Imugene appoints leading cancer researcher to board 01 Oct 2018 - Biotech company, Imugene (ASX:IMU) has today announced the appointment of a leading cancer researcher to its Scientific Advisory Board.
Company News / by Rachael Jones - 2 years ago Imugene starts manufacture of KEY-Vaxx for trials 21 Sep 2018 - Clinical stage immuno-oncology company Imugene (ASX:IMU) has formally commenced cGMP manufacture of the clinical batch of cancer vaccine KEY-Vaxx.
Company News / by Anna Napoli - 2 years ago Imugene completes recruitment for Phase 1b clinical trial of HER-Vaxx 11 Sep 2018 - Immuno-oncology company, Imugene (ASX:IMU) has announced the Phase 1b clinical trial of its cancer vaccine (HER-Vaxx) for gastric cancer patients has completed recrui…
Market Reports / by Jessica Amir - 2 years ago Out of puff on Friday: Aus shares close 0.9% higher on week 08 Jun 2018 - Market Wrap. ASX20, ASX50, ASX100 and ASX200 reshuffled with Afterpay Touch (ASX:APT) & Kidman Resources (ASX:KDR) in ASX200. MMJ PhyoTech (ASX:MMJ) pleased Canada cl…
Interviews / by Rachael Jones - 3 years ago Imugene (ASX:IMU) 1H18 results & outlook 09 March 2018 - Imugene Limited (ASX:IMU) CEO Leslie Chong talks 1H18 and outlook, including progress with the company's lead HER-Vaxx cancer vaccine.
Company News / by Kathy Skantzos - 3 years ago Imugene raises $8.7 million for clinical trial 23 Nov 2017 - Immune-oncology company Imugene (ASX:IMU) raises $8.7 million through a $6.7 million institutional placement and a $2 million fully underwritten entitlement offer.
